• Biotalys, a subsidiary of Ackermans & van Haaren, posted a net loss of EUR 9.14 million in H1 2026, versus EUR 8.14 million.
• Normalized net loss improved to EUR 7.2 million from EUR 8.14 million, reflecting restructuring costs of EUR 1.94 million.
• Cash totaled EUR 11.93 million at June 30, 2026, implying runway through end-Q1 2027.
• Operating cash outflow rose to EUR 7.61 million from EUR 6.09 million, driven by restructuring-related payments.
• Private placement raised EUR 12.05 million; operations refocused on EVOCA NG and BioFun-6 to curb cash burn.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ackermans & van Haaren NV published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.